Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.
Abstract: The present invention provides a transgenic non-human animal, in particular a transgenic mouse encoding the NOX and Duox family of proteins, which generate reactive oxygen intermediates (ROI). The present invention additionally comprises cells and cell lines containing transgenes encoding for members of the NOX and Duox family of proteins. The present invention further comprises methods and compositions for evaluating regulators of abnormal cell growth and in the development of compounds that effect ROI expression.
Type:
Grant
Filed:
July 14, 2003
Date of Patent:
October 10, 2006
Assignee:
Emory University
Inventors:
J. David Lambeth, Guangjie Cheng, James McCoy
Abstract: The present invention discloses a method for treating HIV that includes administering ?-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using ?-D-D4FC as “salvage therapy” to patients which exhibit drug resistance to other anti-HIV agents. ?-D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.
Type:
Grant
Filed:
January 23, 2003
Date of Patent:
October 3, 2006
Assignee:
Emory University
Inventors:
Raymond F. Schinazi, Jennifer L. Hammond, John W. Mellors, Dennis C. Liotta
Abstract: Polyoxometalate topical compositions for removing contaminants from an environment and methods of use thereof are disclosed. An embodiment of the polyoxometalate topical composition includes a topical carrier and at least one polyoxometalate, with the proviso that the polyoxometalate is not H5PV2Mo10O40; K5Si(H2O)MnIIIW11O39; K4Si(H2O)MnIVW11O39; or K5CoIIIW12O40. Another embodiment relates to a method for removing a contaminant from an environment, including contacting the polyoxometalate topical composition with the environment containing the contaminant for a sufficient time to remove the contaminant from the environment.
Type:
Grant
Filed:
April 29, 2002
Date of Patent:
August 29, 2006
Assignee:
Emory University
Inventors:
Craig L. Hill, Ling Xu, Jeffrey T. Rhule, Eric A. Boring
Abstract: A transcription factor capable of activating multiple insulin-responsive genes. In one embodiment, the transcription factor includes an NH2-domain containing thirteen epidermal growth factor (EGF)-like repeats proximate to the N-terminus, a solitary calcium-binding EGF-like domain proximate to the C-terminus, and three consecutive fibronectin type III (fn3) domains between the NH2-domain and the EGF-like domain.
Abstract: The present invention relates to apparatus and methods for electrically inducing and pharmacologically maintaining cardiac asystole. The present invention combines electrostimulation of the vagus nerve to transiently arrest the heart, and the administration of a pharmaceutical composition that suppresses the tendency of the heart to escape from the induced asystolic state. The present invention provides an apparatus to interrogate the response of a heart to an electric pulse applied to the vagus nerve and to select the optimum location of an electrode and pulse to arrest the heart. The present invention further provides embodiments of catheter and tube electrode devices that incorporate expanding electrodes intended to contact the interior walls of blood vessels or anatomic structures in which the electrode devices are implanted. The present invention also provides cutaneous array electrodes that may be used non-invasively to stimulate the vagus nerve.
Abstract: The present disclosure describes DNA damage endonucleases which exhibit broad specificity with respect to the types of structural aberrations in double stranded DNA. These enzymes recognize double stranded DNA with distortions in structure, wherein the distortions result from photoproducts, alkylation, intercalation, abasic sites, mismatched base pairs, insertion deletion loops, cisplatin adducts and other types of base damage (for example, uracil resulting from cytosine deamination). The UVDE (Uve1p) of Schizosaccharomyces pombe, certain truncated forms of that UVDE (lacking from about 100 to about 250 amino acids of N-terminal sequence) and certain endonucleases from Homo sapiens, Neurospora crassa, Bacillus subtilis, Bacillus anthracis, Methanococcus jannaschii, and Deinococcus radiodurans. The present disclosure further provides methods for cleaving double stranded DNA having structural distortions as set forth herein using the exemplified endonucleases or their stable, functional truncated derivatives.
Type:
Grant
Filed:
November 28, 2000
Date of Patent:
June 13, 2006
Assignee:
Emory University
Inventors:
Paul W. Doetsch, Angela M. Avery, Balveen Kaur
Abstract: The use of a 1,3-oxathiolane nucleoside analogue and pharmaceutically acceptable derivatives thereof for the treatment of hepatitis B virus infections is disclosed. Pharmaceutical formulations are also provided.
Abstract: The present invention relates to new genes encoding for the production of novel proteins involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these genes, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these genes and proteins, and methods to determine the activity of drugs to affect the activity of the proteins of the present invention.
Type:
Grant
Filed:
December 13, 2002
Date of Patent:
May 23, 2006
Assignee:
Emory University
Inventors:
J. David Lambeth, Kathy K. Griendling, Bernard P. Lassegue, Rebecca S. Arnold, Guangjie Cheng
Abstract: The present invention is directed to isolated nucleic acid molecules that encode LIM mineralization protein, or LMP. The invention further provides vectors comprising splice variants of nucleotide sequences that encode LMP, as well as host cells comprising those vectors. Moreover, the present invention relates to methods of inducing bone formation by transfecting osteogenic precursor cells with an isolated nucleic acid molecule comprising a nucleotide sequence encoding splice variants of LIM mineralization protein. The transfection may occur ex vivo or in vivo by direct injection of virus or naked plasmid DNA. In a particular embodiment, the invention provides a method of fusing a spine by transfecting osteogenic precursor cells with an isolated nucleic acid molecule having a nucleotide sequence encoding LIM mineralization protein, admixing the transfected osteogenic precursor cells with a matrix and contacting the matrix with the spine.
Abstract: The present invention relates to new genes encoding for the production of novel proteins involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these genes, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these genes and proteins, and methods to determine the activity of drugs to affect the activity of the proteins of the present invention.
Type:
Grant
Filed:
December 13, 2002
Date of Patent:
May 16, 2006
Assignee:
Emory University
Inventors:
J. David Lambeth, Kathy K. Griendling, Bernard P. Lassegue, Rebecca S. Arnold, Guangie Cheng
Abstract: This invention provides a method of inhibiting viable cells transplanted into a subject from being destroyed by the subject's immune system which comprises: a) containing the viable cells, or tissue comprising the viable cells, prior to transplantation within a device comprising a semipermeable membrane; and b) treating the subject with a substance which inhibits an immune-system costimulation event in an amount effective to inhibit the subject's immune system from responding to said contained cells or tissue. In one embodiment, the substance which inhibits an immune-system costimulation event is CTLA4.
Type:
Grant
Filed:
March 27, 1998
Date of Patent:
May 9, 2006
Assignees:
Emory University, Bristol Myers-Squibb Company
Inventors:
Collin J. Weber, Mary K. Hagler, Peter S. Linsley, Judith A. Kapp, Susan A. Safley
Abstract: Briefly described, embodiments of this disclosure include structures, methods of forming the structures, and methods of using the structures. One exemplary structure, among others, includes a nanospecies and a porous material. The nanospecies has a first characteristic and a second detectable characteristic. In addition, a second detectable energy is produced corresponding to the second detectable characteristic upon exposure to a first energy. The porous material has the first characteristic and a plurality of pores. The first characteristic causes the nanospecies to interact with the porous material and become disposed in the pores of the porous material.
Abstract: The present invention provides a vascular conduit device including a deformable flange and complementary securing ring in cooperation for securing the device within an aperture defined in a tissue wall. The present invention further provides a system for implanting such a vascular conduit device in a tissue wall. More specifically, the present invention provides a system including a coring device for defining an aperture in a tissue wall (such as a ventricle and/or a blood vessel) and securely implanting a vascular conduit device therein so as to provide fluid communication between a first and second surface of the tissue wall via the vascular conduit device.
Type:
Application
Filed:
October 14, 2005
Publication date:
April 27, 2006
Applicant:
Emory University
Inventors:
Thomas Vassiliades, Ajit Yoganathan, Jorge Jimenez
Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more amino acids of positions 484-508 of the A2 domain. The modified factor VIII is useful as a clotting factor supplement for hemophiliacs.
Abstract: The present invention relates to nucleotides encoding for the production of novel regulatory proteins for Nox enzymes involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these nucleotides, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these nucleotides and proteins, and methods to determine the activity of drugs to affect the biological activity of the regulatory proteins of the present invention.
Abstract: The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.
Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.
Abstract: The present invention relates to methods of identifying genes involved in memory formation. This is accomplished by performing a gene chip identification of those genes expressed during transcription-dependent memory formation but not during transcription-independent memory formation. A statistical analysis of the gene chip identification output yields a set of genes that are involved in transcription-dependent memory formation.
Type:
Grant
Filed:
March 10, 2000
Date of Patent:
February 28, 2006
Assignees:
Cold Spring Harbor Laboratory, Emory University, Hoffmann-La Roche Inc.
Inventors:
Timothy P. Tully, Joshua I. Dubnau, Michael Davis, Jan Mous, Ulrich Certa